Item 5.07. Submission of Matters to a Vote of Security Holders.
On
Proposal 6 - To approve one or more adjournments of the Annual Meeting to a later date or dates if necessary or appropriate to solicit additional proxies if there are insufficient votes to approve any of the proposals at the time of the Annual Meeting or in the absence of a quorum.
For Against Abstain Broker Non-Votes 48,514,171 11,347,936 759,102 -
Upon the approval of the proposal, the Company adjourned the Annual Meeting. During the period of the adjournment, the Company will continue to solicit votes from its stockholders with respect to the proposals for the Annual Meeting.
Stockholders will be able to attend the adjourned Annual Meeting when it is
reconvened at the offices of
The close of business on
Item 7.01. Regulation FD Disclosure.
On
The information in this Item 7.01, and Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
99.1 Press release issued byBrickell Biotech, Inc. onMay 3, 2022 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Cautionary Note Regarding Forward-Looking Statements
Any statements made in this document and its attachment relating to future
financial, business, and/or research and clinical performance, conditions,
plans, prospects, trends, or strategies and other such matters, including
without limitation, Brickell's strategy; future operations; future financial
position; future liquidity; future revenue; territorial focus; projected
expenses; results of operations; the anticipated timing, scope, design,
progress, results, and/or reporting of data of ongoing and future non-clinical
and clinical trials; intellectual property rights, including the acquisition,
validity, term, and enforceability of such; the expected timing and/or results
of regulatory submissions and approvals; and prospects for commercializing any
product candidates of Brickell or third parties, or research and/or licensing
collaborations with, or actions of, its partners, including in
--------------------------------------------------------------------------------
and uncertainties, which change over time, often quickly, and in unanticipated
ways. Important factors that may cause actual results to differ materially from
the results discussed in the forward-looking statements or historical experience
include risks and uncertainties, including without limitation, research results
and data that do not meet targets, expectations, or regulatory approval
requirements; ability to obtain adequate financing for product development,
regulatory submissions, and any commercialization; ability to acquire, maintain,
and enforce intellectual property rights; potential delays or alterations in
product development, trials of any type, and regulatory submission and reviews;
changes in law or policy; litigation; regulatory agency feedback or requests;
supply chain disruptions; unanticipated demands on cash resources; disruptions
and negative effects related to the COVID-19 pandemic and/or the conflict in
Further information on the factors and risks that could cause actual results to
differ from any forward-looking statements are contained in Brickell's filings
with the
--------------------------------------------------------------------------------
© Edgar Online, source